Floatz logo

Ambroxol

Gaucher Disease, Type 3

Agyany Pharma LTDSmall moleculeN/AActive
D
30/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
15/ 100
Competitive Position
95/ 100

Competitive context

6 Active assets in the Gaucher Disease, Type 3 cohort.

Asset / SponsorPhaseRating
Elelyso
Ari Zimran
Phase 4BB
Cerezyme
Sanofi
Phase 3BB
Eliglustat
Sanofi
Phase 3BB
Venglustat
Sanofi
Phase 3B
Velaglucerase Alfa
Shire
Phase 1/2CCC

View all 10 →

Same molecule, other indications

Ambroxol is also rated in:

Parkinson diseaseDormant
BB
Indicative ·
65 / 100
View asset →
GBA1-related Parkinson disease, susceptibilityDormant
BB
Indicative ·
64 / 100
View asset →
mucus inspissation of respiratory tractDormant
BB
Indicative ·
64 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →